Genentech’s Gregory Rippon, M.D., associates a few different phrases with the challenging nature of Alzheimer’s disease drug development: “cautious optimism,” “steady progress,” “an exercise in per | Genentech has been working on gantenerumab for 20 years, and, while it’s tempting to try to rush the clinical process, the Roche unit is slowly but surely following the evidence.